AFA
ANIK icon

Alta Fundamental Advisers’s Anika Therapeutics ANIK Stock Holding History

Alta Fundamental Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-454,944
Closed -$4.81M – 28
2025
Q2 		$4.81M Sell
454,944
-16,030
-3% -$202K 2.47% 16
2025
Q1 		$7.08M Sell
470,974
-229,458
-33% -$3.82M 4.55% 9
2024
Q4 		$11.5M Buy
700,432
+404,350
+137% +$7.98M 3.45% 12
2024
Q3 		$7.31M Hold
296,082
– – 2.11% 14
2024
Q2 		$7.5M Buy
296,082
+34,700
+13% +$899K 2.38% 11
2024
Q1 		$6.64M Buy
261,382
+68,838
+36% +$1.67M 2.51% 9
2023
Q4 		$4.36M Buy
+192,544
New +$3.98M 1.97% 11

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Alta Fundamental Advisers's ANIK Position: Q3 2025 in Review

Alta Fundamental Advisers sold out of Anika Therapeutics (ANIK) in Q3 2025, closing a stake of 454,944 shares — an estimated $4.81M sold.

Alta Fundamental Advisers first reported a position in ANIK in Q4 2023 and held it in 7 quarters. The position peaked at $11.5M in Q4 2024. 117 funds tracked by Wall St. Rank hold ANIK as of Q3 2025.

  • Alta Fundamental Advisers reported no remaining Anika Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Alta Fundamental Advisers sold 454,944 Anika Therapeutics shares in Q3 2025, an estimated $4.81M.
  • Alta Fundamental Advisers first reported a position in Anika Therapeutics in Q4 2023 and held it in 7 quarters.
  • Alta Fundamental Advisers's Anika Therapeutics position peaked at $11.5M in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2025.

Based on Alta Fundamental Advisers's 13F filing for Q3 2025, filed 13 Nov 2025.